Middle age has historically been an understudied period of life compared to older age, when
cognitive and brain health decline are most pronounced, but the scope for intervention may …

Introduction Despite a large preclinical literature demonstrating neuroprotective effects of
estrogen, use of menopausal hormone therapy (HT) for Alzheimer's disease (AD) risk …

Introduction Despite evidence from preclinical studies suggesting estrogen's neuroprotective
effects, the use of menopausal hormone therapy (MHT) to support cognitive function remains …

Sex and gender—biological and social constructs—significantly impact the prevalence of
protective and risk factors, influencing the burden of Alzheimer's disease (AD; amyloid beta …

Background White matter hyperintensities are an important marker of cerebral small vessel
disease. This disease burden is commonly described as hyperintense areas in the cerebral …

Background The vast majority of women with dementia are post-menopausal. Despite
clinical relevance, menopause is underrepresented in rodent models of dementia. Before …

It is well known that vascular factors and specific social determinants of health contribute to
dementia risk and that the prevalence of these risk factors differs according to race and sex …

Abstract Introduction White matter hyperintensities (WMHs) are common magnetic
resonance imaging (MRI) findings in the aging population in general, as well as in patients …

Background and Objectives Mounting evidence supports sex differences in Alzheimer
disease (AD) risk. Vascular and hormonal factors may together contribute to AD risk in …

Brain age refers to age predicted by brain features. Brain age has previously been
associated with various health and disease outcomes and suggested as a potential …